{"title":"Introduction to the Polish branch of the INNODIA program","authors":"Paulina Pokrywka, H. Kaminska, P. Jarosz-Chobot","doi":"10.5114/pedm.2023.125365","DOIUrl":null,"url":null,"abstract":"Type 1 diabetes (T1D) is an autoimmune disease in which the beta cells of the pancreas that produce insulin are destroyed by T lymphocytes [1]. According to the World Health Organization, in 2019 alone, diabetes was the direct cause of 1.5 million deaths [2]. So far, the disease process is not fully understood, and a cure has not yet been developed, which is why diabetes is one of the priority diseases under research in the World Health Organization’s first and second programmes of Innovative Medicines Initiative (IMI1 and IMI2) [3]. Of the 13 projects funded by IMI until October 2019, only one was targeted to type 1 diabetes – INNODIA [3].","PeriodicalId":39165,"journal":{"name":"Pediatric Endocrinology, Diabetes and Metabolism","volume":"C-27 1","pages":"57 - 58"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Endocrinology, Diabetes and Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pedm.2023.125365","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Type 1 diabetes (T1D) is an autoimmune disease in which the beta cells of the pancreas that produce insulin are destroyed by T lymphocytes [1]. According to the World Health Organization, in 2019 alone, diabetes was the direct cause of 1.5 million deaths [2]. So far, the disease process is not fully understood, and a cure has not yet been developed, which is why diabetes is one of the priority diseases under research in the World Health Organization’s first and second programmes of Innovative Medicines Initiative (IMI1 and IMI2) [3]. Of the 13 projects funded by IMI until October 2019, only one was targeted to type 1 diabetes – INNODIA [3].
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
